OUTLOOK THERAPEUTICS, INC. Operating Cash Flow
OUTLOOK THERAPEUTICS, INC. (OTLK) reported Operating Cash Flow of -$43.78 million for the 9-month period ending 2026-06-30, per its 10-Q filed 2026-08-18.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-18
- OUTLOOK THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$21.01M.
- OUTLOOK THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$7.83M.
- OUTLOOK THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$14.94M.
- OUTLOOK THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$12.38M.
- OUTLOOK THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2025 was -$51.83M.
- OUTLOOK THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2024 was -$68.79M.
- OUTLOOK THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2023 was -$42.97M.
- OUTLOOK THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2022 was -$56.67M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 3 month as first filed | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 6 month as first filed | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 9 month as first filed | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$21.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-08-18 | -$28.84M derived: sum of 2 quarters · filed 2026-08-18 | -$43.78M 10-Q · filed 2026-08-18 | -$56.15M derived: sum of 4 quarters · filed 2026-08-18 | |||
| 2026-03-31 | -$7.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-05-15 | -$22.77M 10-Q · filed 2026-05-15 | -$35.14M derived: sum of 3 quarters · filed 2026-05-15 | -$47.05M derived: sum of 4 quarters · filed 2026-08-18 | |||
| 2025-12-31 | -$14.94M 10-Q · filed 2026-02-17 | -$27.32M derived: sum of 2 quarters · filed 2026-02-17 | -$39.22M derived: sum of 3 quarters · filed 2026-08-18 | -$55.80M derived: sum of 4 quarters · filed 2026-08-18 | |||
| 2025-09-30 | -$12.38M derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-19 | -$24.28M derived: sum of 2 quarters · filed 2026-08-18 | -$40.86M derived: sum of 3 quarters · filed 2026-08-18 | -$51.83M 10-K · filed 2025-12-19 | |||
| 2025-06-30 | -$11.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-08-18 | -$28.48M derived: sum of 2 quarters · filed 2026-08-18 | -$39.45M 10-Q · filed 2026-08-18 | -$56.43M derived: sum of 4 quarters · filed 2026-08-18 | |||
| 2025-03-31 | -$16.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-05-15 | -$27.55M 10-Q · filed 2026-05-15 | -$44.53M derived: sum of 3 quarters · filed 2026-05-15 | -$64.05M derived: sum of 4 quarters · filed 2026-05-15 | |||
| 2024-12-31 | -$10.97M 10-Q · filed 2026-02-17 | -$27.95M derived: sum of 2 quarters · filed 2026-02-17 | -$47.46M derived: sum of 3 quarters · filed 2026-02-17 | -$66.73M derived: sum of 4 quarters · filed 2026-02-17 | |||
| 2024-09-30 | -$16.98M derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-19 | -$36.49M derived: sum of 2 quarters · filed 2025-12-19 | -$55.76M derived: sum of 3 quarters · filed 2025-12-19 | -$68.79M 10-K · filed 2025-12-19 | |||
| 2024-06-30 | -$19.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-08-14 | -$38.78M derived: sum of 2 quarters · filed 2025-08-14 | -$51.81M 10-Q · filed 2025-08-14 | -$64.55M derived: sum of 4 quarters · filed 2025-08-14 | |||
| 2024-03-31 | -$19.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-05-15 | -$32.30M 10-Q · filed 2025-05-15 | -$45.04M derived: sum of 3 quarters · filed 2025-05-15 | -$58.26M derived: sum of 4 quarters · filed 2025-05-15 | |||
| 2023-12-31 | -$13.03M 10-Q · filed 2025-02-14 | -$25.77M derived: sum of 2 quarters · filed 2025-02-14 | -$38.99M derived: sum of 3 quarters · filed 2025-02-14 | -$47.10M derived: sum of 4 quarters · filed 2025-02-14 | |||
| 2023-09-30 | -$12.74M derived: 10-K 12 month − 10-Q 9 month · filed 2024-12-27 | -$25.96M derived: sum of 2 quarters · filed 2024-12-27 | -$34.07M derived: sum of 3 quarters · filed 2024-12-27 | -$42.97M 10-K · filed 2024-12-27 | |||
| 2023-06-30 | -$13.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-08-14 | -$21.33M derived: sum of 2 quarters · filed 2024-08-14 | -$30.23M 10-Q · filed 2024-08-14 | -$40.48M derived: sum of 4 quarters · filed 2024-08-14 | |||
| 2023-03-31 | -$8.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-05-15 | -$17.02M 10-Q · filed 2024-05-15 | -$27.27M derived: sum of 3 quarters · filed 2024-05-15 | -$48.37M derived: sum of 4 quarters · filed 2024-05-15 | |||
| 2022-12-31 | -$8.90M 10-Q · filed 2024-02-14 | -$19.15M derived: sum of 2 quarters · filed 2024-02-14 | -$40.25M derived: sum of 3 quarters · filed 2024-02-14 | -$54.59M derived: sum of 4 quarters · filed 2024-02-14 | |||
| 2022-09-30 | -$10.25M derived: 10-K 12 month − 10-Q 9 month · filed 2023-12-22 | -$31.35M derived: sum of 2 quarters · filed 2023-12-22 | -$45.68M derived: sum of 3 quarters · filed 2023-12-22 | -$56.67M 10-K · filed 2023-12-22 | |||
| 2022-06-30 | -$21.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-08-14 | -$35.43M derived: sum of 2 quarters · filed 2023-08-14 | -$46.42M 10-Q · filed 2023-08-14 | -$55.41M derived: sum of 4 quarters · filed 2023-08-14 | |||
| 2022-03-31 | -$14.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-05-15 | -$25.32M 10-Q · filed 2023-05-15 | -$34.31M derived: sum of 3 quarters · filed 2023-05-15 | -$54.51M derived: sum of 4 quarters · filed 2023-05-15 | |||
| 2021-12-31 | -$10.99M 10-Q · filed 2023-02-14 | -$19.98M derived: sum of 2 quarters · filed 2023-02-14 | -$40.17M derived: sum of 3 quarters · filed 2023-02-14 | -$51.92M derived: sum of 4 quarters · filed 2023-02-14 | |||
| 2021-09-30 | -$8.99M derived: 10-K 12 month − 10-Q 9 month · filed 2022-12-29 | -$29.18M derived: sum of 2 quarters · filed 2022-12-29 | -$40.93M derived: sum of 3 quarters · filed 2022-12-29 | -$54.25M 10-K · filed 2022-12-29 | |||
| 2021-06-30 | -$20.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-08-10 | -$31.94M derived: sum of 2 quarters · filed 2022-08-10 | -$45.26M 10-Q · filed 2022-08-10 | -$57.34M derived: sum of 4 quarters · filed 2022-08-10 | |||
| 2021-03-31 | -$11.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-05-13 | -$25.07M 10-Q · filed 2022-05-13 | -$37.15M derived: sum of 3 quarters · filed 2022-05-13 | -$43.10M derived: sum of 4 quarters · filed 2022-05-13 | |||
| 2020-12-31 | -$13.32M 10-Q · filed 2022-02-14 | -$25.40M derived: sum of 2 quarters · filed 2022-02-14 | -$31.36M derived: sum of 3 quarters · filed 2022-02-14 | -$38.44M derived: sum of 4 quarters · filed 2022-02-14 | |||
| 2020-09-30 | -$12.08M derived: 10-K 12 month − 10-Q 9 month · filed 2021-12-23 | -$18.03M derived: sum of 2 quarters · filed 2021-12-23 | -$25.12M derived: sum of 3 quarters · filed 2021-12-23 | -$31.79M 10-K · filed 2021-12-23 | |||
| 2020-06-30 | -$5.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-08-13 | -$13.04M derived: sum of 2 quarters · filed 2021-08-13 | -$19.71M 10-Q · filed 2021-08-13 | -$25.65M derived: sum of 4 quarters · filed 2021-08-13 | |||
| 2020-03-31 | -$7.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-05-14 | -$13.76M 10-Q · filed 2021-05-14 | -$19.70M derived: sum of 3 quarters · filed 2021-05-14 | -$30.01M derived: sum of 4 quarters · filed 2021-05-14 | |||
| 2019-12-31 | -$6.67M 10-Q · filed 2021-02-16 | -$12.62M derived: sum of 2 quarters · filed 2021-02-16 | -$22.92M derived: sum of 3 quarters · filed 2021-02-16 | -$29.18M derived: sum of 4 quarters · filed 2021-02-16 | |||
| 2019-09-30 | -$5.94M derived: 10-K 12 month − 10-Q 9 month · filed 2020-12-23 | -$16.25M derived: sum of 2 quarters · filed 2020-12-23 | -$22.51M derived: sum of 3 quarters · filed 2020-12-23 | -$32.29M 10-K · filed 2020-12-23 | |||
| 2019-06-30 | -$10.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-08-14 | -$16.57M derived: sum of 2 quarters · filed 2020-08-14 | -$26.35M 10-Q · filed 2020-08-14 | -$26.37M 10-Q · filed 2019-08-14 | -$34.74M derived: sum of 4 quarters · filed 2020-08-14 | ||
| 2019-03-31 | -$6.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-05-15 | -$16.04M 10-Q · filed 2020-05-15 | -$16.06M 10-Q · filed 2019-05-15 | -$24.43M derived: sum of 3 quarters · filed 2020-05-15 | -$32.97M derived: sum of 4 quarters · filed 2020-05-15 | ||
| 2018-12-31 | -$9.78M 10-Q · filed 2020-02-14 | -$9.80M 10-Q · filed 2019-02-14 | -$18.18M derived: sum of 2 quarters · filed 2020-02-14 | -$26.71M derived: sum of 3 quarters · filed 2020-02-14 | -$34.15M derived: sum of 4 quarters · filed 2020-02-14 | ||
| 2018-09-30 | -$8.39M derived: 10-K 12 month − 10-Q 9 month · filed 2019-12-19 | -$16.93M derived: sum of 2 quarters · filed 2019-12-19 | -$24.37M derived: sum of 3 quarters · filed 2019-12-19 | -$33.04M 10-K · filed 2019-12-19 | |||
| 2018-06-30 | -$8.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-08-14 | -$15.97M derived: sum of 2 quarters · filed 2019-08-14 | -$24.65M 10-Q · filed 2019-08-14 | -$24.57M derived: sum of 4 quarters · filed 2019-08-14 | |||
| 2018-03-31 | -$7.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-05-15 | -$16.11M 10-Q · filed 2019-05-15 | -$16.03M derived: sum of 3 quarters · filed 2019-05-15 | ||||
| 2017-12-31 | -$8.67M 10-Q · filed 2019-02-14 | -$8.59M derived: sum of 2 quarters · filed 2019-02-14 | |||||
| 2017-09-30 | $79.85K derived: 10-K 12 month − 10-Q 9 month · filed 2018-12-18 | -$15.51M 10-K · filed 2018-12-18 | |||||
| 2017-06-30 | -$15.58M 10-Q · filed 2018-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |